To: [redacted])[[redacted]@minvws.nl]
Cc: [redacted]@rivm.nl[[redacted]@rivm.nl]; [redacted]@rivm.nl[[redacted]@rivm.nl]; [redacted]. ([redacted])[[redacted]@minvws.nl]; [redacted])[[redacted]@minvws.nl]; [redacted])[[redacted]@minvws.nl]; [redacted])[[redacted]@minvws.nl]; [redacted])[[redacted]@minvws.nl]; [redacted]@ec.europa.eu[[redacted]@ec.europa.eu]
From: [redacted]@ec.europa.eu
Sent: Fri 8/7/2020 6:13:47 AM
Subject: FW: Veklury (remdesivir) 1st instalment NL
Received: Fri 8/7/2020 6:14:15 AM

Dear colleagues,

We have been advised that delivery will take place today, 07/08.

Best regards,

[redacted]

From: [redacted]) < [redacted]@minvws.nl>
Sent: Wednesday, August 5, 2020 11:40 AM
To: [redacted] < [redacted]@ec.europa.eu>
Cc: [redacted] < [redacted]@rivm.nl>; [redacted] < [redacted]@rivm.nl>; [redacted]) < [redacted]@minvws.nl>; [redacted]) < [redacted]@minvws.nl>; [redacted]) < [redacted]@minvws.nl>; [redacted]) < [redacted]@minvws.nl>; [redacted]) < [redacted]@minvws.nl>
Subject: RE: Veklury (remdesivir) 1st instalment

Dear [redacted]

Thank you for your correspondence. We acknowledge the note.

Warm regards,

[redacted]
[redacted]
Division of Crisis control and communicable diseases

Ministry of Health, Welfare and Sport
Directorate of Public Health
Parnassusplein 5 | 2511 VX The Hague
PO BOX 20350 | 2500 EJ The Hague
The Netherlands

Van: [redacted]@ec.europa.eu < [redacted]@ec.europa.eu>
Verzonden: dinsdag 4 augustus 2020 19:26
Aan: [redacted]@ec.europa.eu
Onderwerp: Veklury (remdesivir) 1st instalment

Dear Health Security Committee,

As a follow up to below, please find attached an information note regarding the supply of Veklury (remdesivir). As per the note, you are asked to acknowledge this. The corresponding deadline is to receive this acknowledgement **by 12pm(midday) tomorrow, 05/08**. Please note that we cannot initiate delivery of the product until this is received.

We also asked countries to reply by today, 04/08, 15h for confirmation of the order forms. Thank you for countries that have replied. We note that the majority have not replied, and as per the indication in our email, in case no reaction is received, agreement is presumed.

Finally, we also attach the packaging dimensions for your information.

Kind regards,

5.1.2e

From: 5.1.5 < 5.1.2e @ec.europa.eu>
Sent: Thursday, July 30, 2020 4:21 PM
Cc: 5.1.5 < 5.1.2e @ec.europa.eu>
Subject: Veklury (remdesivir) 1st instalment

Dear Health Security Committee,

As a follow up to below emails, we write to inform you that a contract has been concluded between the Commission and Gilead for the supply of Veklury (remdesivir) under the Emergency Support Instrument.

The supply will occur in three instalments, once in August, once in September and once in October. This is broken down as follows:

5.1.1c

Country	Estimated number of remdesivir vials allocated
5.1.2a	

5.1.2a	
Total	**43750**

2nd Instalment & 3rd instalment

- Closer to the time of delivery, the ECDC allocation will be rerun so to allocate the available product
- We will be in touch to advise on final allocations in due course

Please let us know if there are any remaining questions.

Kind regards,

5.1.2e

From: 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>
Sent: Sunday, July 26, 2020 1:42 PM
To: 5.1.2e @ec.europa.eu; 5.1.2e @ec.europa.eu
Subject: Remdesivir - update following HSC meeting of 21 July 2020

Dear Health Security Committee,

Further to below e-mail below regarding the foreseen purchase of "Velkury" (remdesivir) via the Emergency Support Instrument, many thanks to all who have replied already.

For those who have not replied or did not send a shipping address yet, **please note the extended deadline submit this information is Monday 27 July 2020 – 10:00 hrs (CEST). Failure to receive this information by this deadline may result in an inability to process your country's expression of interest.**

Kind regards,

5.1.2e

De : 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>
Envoyé : mercredi 22 juillet 2020 18:34
Objet : Remdesivir - update following HSC meeting of 21 July 2020

Dear Health Security Committee,

Further to the information we provided yesterday in the Health Security Committee, we would like to inform you that the negotiations with Gilead to buy Veklury (remdesivir) under the Emergency Support Instrument (ESI) are advancing.

As you are probably aware, Veklury received a conditional marketing authorization for the treatment of Covid-19 patients from the European Commission on 3 July 2020. For detailed information about Veklury, please visit:

https://www.ema.europa.eu/en/medicines/human/EPAR/veklury#authorisation-details-section

If your country would be interested to receive Veklury purchased under the ESI, please inform us of an expression of interest by replying to this e-mail. We will also need to receive from you a foreseen place of delivery, which fits pharmaceutical delivery requirements. This information should include a full address including the name of a contact person (e-mail address, phone number). Delivery would take place only to one designated address, and countries are asked to organise the distribution to hospitals from there. Veklury would be delivered as commercial product in a lyophilised form.

Please note that the **deadline to submit this information is Friday 24 July 2020 – 17:00 hrs (CEST). Failure to receive this information by this deadline may result in an inability to process your country's expression of interest.**

For any further developments ,we will keep you informed as soon as possible, and latest once a contract for this procurement has been concluded.

Many thanks.

Kind regards,

5.1.2e